Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease
Metastatic Extramammary Paget's disease (EMPD) is an extremely rare cancer without standard treatment. Treatment with the antibody-drug conjugate DV (an anti-HER2 antibody-drug conjugate) elicited an objective response in 8 of the 11 patients (73%), and CEA response in 10 of the 11 patients (91%). This efficacy was accompanied by mild treatment-related toxicity. Antibody-drug conjugate targeting of HER2 might be an active treatment for metastatic EMPD.
Authors
- Jiong Hu (ORCID: https://orcid.org/0000-0002-5613-1195)
- Juan Zhou (ORCID: https://orcid.org/0000-0002-3040-0238)
- Wangjun Yan (ORCID: https://orcid.org/0000-0001-9178-0687)
- Wenxia Peng
- Wenfeng Li (ORCID: https://orcid.org/0000-0001-7213-8648)
- Sheng Zhang (ORCID: https://orcid.org/0000-0002-0109-6951)
- Xiaoying Zhao (ORCID: https://orcid.org/0000-0003-4116-2105)
- Mingjuan Sun
- Hualei Gan
Institutions
- Qingdao University (CN)
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf063
- Primary Topic
- Cancer and Skin Lesions
- Type
- article
- Field-Weighted Citation Impact
- 0.00